In the pivotal ADAURA trial, adjuvant therapy with the third-generation EGFR-TKI osimertinib significantly prolonged disease-free survival (DFS) of EGFR-mutant NSCLC patients compared with the placebo. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.